PD-1抑制剂联合仑伐替尼治疗晚期肝癌的疗效分析  

Analysis of efficacy of PD-1 inhibitor combined with renvatinib in the treatment of advanced liver cancer

作　　者：付慧英 柯传庆[1] 章柏平[1] 彭恩兰 FU Huiying;KE Chuanqing;ZHANG Baiping;PENG Enlan(Department of Oncology,908 Hospital,Joint Service Support Force of the Chinese People’s Liberation Army,Nanchang 330000,China)

机构地区：[1]中国人民解放军联勤保障部队908医院肿瘤科,南昌330000

出　　处：《上海医药》2022年第3期29-30,66,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探讨分析PD-1抑制剂联合仑伐替尼治疗晚期肝癌临床效果和不良反应。方法:将66例晚期肝癌患者随机分为对照组(n=33,给予仑伐替尼治疗)和观察组(n=33,给予PD-1抑制剂联合仑伐替尼治疗),对比两组临床治疗效果和不良发生情况。结果:观察组肝区疼痛缓解有效率高于对照组(81.8%vs 54.5%),不良反应发生率低于对照组(12.1%vs 45.5%),靶病灶治疗总有效率高于对照组(75%vs 45%,均P<0.05)。结论:PD-1抑制剂联合仑伐替尼治疗晚期肝癌临床效果显著,且可降低不良反应发生率。Objective:To investigate the clinical effect and adverse reactions of PD-1 inhibitor combined with renvatinib in the treatment of advanced liver cancer.Methods:Sixty-six patients with advanced liver cancer were randomly divided into a control group(n=33,treated with ranvatinib)and an observation group(n=33,treated with PD-1 inhibitor combined with ranvatinib).The clinical effects and adverse events were compared between the two groups.Results:The effective rate of pain relief in the liver region of the observation group was higher than that of the control group(81.8%vs 54.5%),the incidence of adverse reactions was lower(12.1%vs 45.5%)and the overall response rate of the target lesion treatment was higher(75%vs 45%,all P<0.05)in the observation group than the control group.Conclusion:The clinical effect of PD-1 inhibitor combined with ranvatinib for the treatment of advanced liver cancer is significant,and furthermore the incidence of adverse reactions can be reduced.

关 键 词：晚期肝癌 PD-1抑制剂 仑伐替尼 临床效果 不良反应 

分 类 号：R979.19[医药卫生—药品] R735.7[医药卫生—药学]